R&G PharmaStudies Co. Ltd. A (301333) - Total Liabilities

Latest as of June 2025: CN¥418.40 Million CNY ≈ $61.22 Million USD

Based on the latest financial reports, R&G PharmaStudies Co. Ltd. A (301333) has total liabilities worth CN¥418.40 Million CNY (≈ $61.22 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore R&G PharmaStudies Co. Ltd. A (301333) cash flow conversion to assess how effectively this company generates cash.

R&G PharmaStudies Co. Ltd. A - Total Liabilities Trend (2019–2024)

This chart illustrates how R&G PharmaStudies Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Check R&G PharmaStudies Co. Ltd. A asset resilience ratio to evaluate the company's liquid asset resilience ratio.

R&G PharmaStudies Co. Ltd. A Competitors by Total Liabilities

The table below lists competitors of R&G PharmaStudies Co. Ltd. A ranked by their total liabilities.

Company	Country	Total Liabilities
Allied Properties Real Estate Investment Trust TO:AP-UN	Canada	CA$5.24 Billion
Asuransi Jiwa Sinarmas Msig PT JK:LIFE	Indonesia	Rp6.71 Trillion
ABCELLERA BIOLOGICS F:8QQ	Germany	€390.05 Million
Baotou Huazi Industry Co Ltd SHG:600191	China	CN¥628.63 Million
LGI Homes NASDAQ:LGIH	USA	$1.83 Billion
Ningbo Runhe High-Tech Materials Co Ltd Class A SHE:300727	China	CN¥454.61 Million
Jiangsu Baichuan HighTech New Materials Co Ltd SHE:002455	China	CN¥10.20 Billion
Zhejiang China Light & Textile Industrial City Group Co Ltd SHG:600790	China	CN¥6.25 Billion

Liability Composition Analysis (2019–2024)

This chart breaks down R&G PharmaStudies Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 301333 company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	5.52	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.22	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.18	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how R&G PharmaStudies Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for R&G PharmaStudies Co. Ltd. A (2019–2024)

The table below shows the annual total liabilities of R&G PharmaStudies Co. Ltd. A from 2019 to 2024.

Year	Total Liabilities	Change
2024-12-31	CN¥500.09 Million ≈ $73.18 Million	+56.69%
2023-12-31	CN¥319.17 Million ≈ $46.70 Million	+10.31%
2022-12-31	CN¥289.35 Million ≈ $42.34 Million	+20.73%
2021-12-31	CN¥239.66 Million ≈ $35.07 Million	+20.20%
2020-12-31	CN¥199.38 Million ≈ $29.17 Million	+1.15%
2019-12-31	CN¥197.12 Million ≈ $28.84 Million	--

About R&G PharmaStudies Co. Ltd. A

SHE:301333 China Biotechnology

Market Cap

$901.11 Million

CN¥6.16 Billion CNY

Market Cap Rank

#9581 Global

#2667 in China

Share Price

CN¥63.76

Change (1 day)

+0.46%

52-Week Range

CN¥43.85 - CN¥91.20

All Time High

CN¥91.20